Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS). (17th September 2020)

• Record Type: Journal Article
• Authors: Yun, Sergi; Enjuanes, Cristina; Calero, Esther; Hidalgo, Encarnación; Cobo, Marta; Llàcer, Pau; García‐Pinilla, José Manuel; González‐Franco, Álvaro; Núñez, Julio; Morales‐Rull, José Luis; Beltrán, Paola; Delso, Cristina; Freixa‐Pamias, Román; Moliner, Pedro; Corbella, Xavier; Comín‐Colet, Josep
• Is Part Of: ESC heart failure. Volume 7:Number 6(2020)
• Page Start: 4448
• Page End: 4457
• Publication Date: 2020-09-17
• Subjects: Chronic heart failure -- Telemedicine -- mHealth -- Outcomes research -- Chronic care model -- Transitional care; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.12962
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: The role of non‐invasive telemedicine (TM) combining telemonitoring and teleintervention by videoconference (VC) in patients recently admitted due to heart failure (HF) ('vulnerable phase' HF patients) is not well established. The aim of the Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS) trial is to assess the impact on clinical outcomes of implementing a TM service based on mobile health (mHealth), which includes remote daily monitoring of biometric data and symptom reporting (telemonitoring) combined with VC structured, nurse‐based follow‐up (teleintervention). The results will be compared with those of the comprehensive HF usual care (UC) strategy based on face‐to‐face on‐site visits at the vulnerable post‐discharge phase. Methods and results: We designed a 24 week nationwide, multicentre, randomized, controlled, open‐label, blinded endpoint adjudication trial to assess the effect on cardiovascular (CV) mortality and non‐fatal HF events of a TM‐based comprehensive management programme, based on mHealth, for patients with chronic HF. Approximately 508 patients with a recent hospital admission due to HF decompensation will be randomized (1:1) to either structured follow‐up based on face‐to‐face appointments (UC group) or the delivery of health care using TM. The primary outcome will be a composite of death from CV causes or non‐fatal HF events (first and recurrent) at the end of a 6 month follow‐up period. Key secondary endpoints will include components of the primary event analysis, recurrent event analysis, and patient‐reported outcomes. Conclusions: The HERMeS trial will assess the efficacy of a TM‐based follow‐up strategy for real‐world 'vulnerable phase' HF patients combining telemonitoring and teleintervention.